Concordia Healthcare Corp (TSE:CXR) had its price objective hoisted by research analysts at TD Securities from C$7.00 to C$14.00 in a report released on Monday. The brokerage presently has a “hold” rating on the stock. TD Securities’ target price would suggest a potential upside of 107.10% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. Goldman Sachs Group Inc. decreased their price objective on Concordia Healthcare Corp from C$34.00 to C$17.00 in a report on Monday, August 15th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a C$73.00 target price on shares of Concordia Healthcare Corp in a research report on Thursday, May 26th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of C$27.25.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/concordia-healthcare-corp-cxr-price-target-lowered-to-c7-00-at-td-securities.html

Concordia Healthcare Corp (TSE:CXR) traded up 2.66% on Monday, reaching $6.94. The company’s stock had a trading volume of 322,512 shares. The firm has a 50 day moving average of $13.06 and a 200 day moving average of $28.33. Concordia Healthcare Corp has a 12 month low of $6.33 and a 12 month high of $95.21. The firm’s market cap is $354.06 million.

Receive News & Ratings for Concordia Healthcare Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia Healthcare Corp and related companies with MarketBeat.com's FREE daily email newsletter.